The Effect of Erythropoietin Therapy and Hemoglobin Levels on the Immune Response to Engerix-B Vaccination in Chronic Kidney Disease

Figures & data

Table 1. Baseline characteristics of the patients enrolled in the study

Group	n	Engerix-B (µg)	rEPO (units/kg/w)	Sex (m/f)	Age (years)	Scr (mg/dL)	CCT (mL/min)	Hb (gr/dL)
A	34	40	80	18/16	62.2 ± 15	—	—	10.2 ± 1.8
B	36	40	—	18/18	59.2 ± 11	3.1 ± 1.1	26.0 ± 5.0	11.7 ± 0.4
C	33	40	80	17/16	61.5 ± 10	3.5 ± 1.0	21.9 ± 6.7	11.5 ± 0.5

Figure 1. Development of protective anti-HBs titers in hemodialysis patients (Group A), predialytic patients who had not been treated with rEPO (Group B) and predialytic patients who are being on rEPO therapy (Group C).

Figure 2. Effect of baseline hemoglobin on the outcome of vaccination with Engerix-B in CKD.